Nordic Nanovector announces the appointment of Gabriele Elbl as Vice President Global Regulatory Affairs.
Elbl is a pharmacist with more than 20 years’ experience working in small and large pharmaceutical companies and at the European Medicines Agency (EMA). She brings expertise in all regulatory aspects of pharmaceutical development and submission procedures for biologicals and small molecules in Europe and in the US with focus on oncology and haematologic malignancies.
“Gabriele is an important hire for Nordic Nanovector, bringing significant valuable expertise to the senior management team. She will play a pivotal role in refining and executing our regulatory strategy for Betalutin in non-Hodgkin’s lymphoma. We are pleased to welcome Gabriele to the team,” says Eduardo Bravo, Nordic Nanovector’s Chief Executive Officer.
Senior leadership roles
Elbl joined Nordic Nanovector on 1 November 2019 from Mundipharma EDO, where she was Global Head of Regulatory Affairs Oncology. Prior to this she held senior leadership roles in global regulatory affairs at MorphoSys, Wilex and Sanofi-Winthrop (part of Sanofi).
Elbl is a German citizen and holds a Ph.D. from the Institute of Pharmaceutical Biology from the Ludwig-Maximilians-University in Munich, Germany.
“I am delighted to join Nordic Nanovector at this important time as we look to accelerate the preparations for the regulatory filings for Betalutin, both in the US and Europe. As a single administration treatment, this novel targeted radioimmunotherapy offers a clearly differentiated therapy option for patients with non-Hodgkin’s lymphoma. I look forward to bringing my knowledge and making a contribution to Nordic Nanovector during this exciting phase of its development,” says Gabriele Elbl.